| Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) JM Bueno-de-Mesquita, WH van Harten, VP Retel, LJ van't Veer, ... The lancet oncology 8 (12), 1079-1087, 2007 | 344 | 2007 |
| Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma MW Rohaan, TH Borch, JH Van Den Berg, Ö Met, R Kessels, ... New England Journal of Medicine 387 (23), 2113-2125, 2022 | 323 | 2022 |
| A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study CA Drukker, JM Bueno‐de‐Mesquita, VP Retèl, WH van Harten, ... International journal of cancer 133 (4), 929-936, 2013 | 300 | 2013 |
| Impact of organ-on-a-chip technology on pharmaceutical R&D costs N Franzen, WH van Harten, VP Retèl, P Loskill, ... Drug discovery today 24 (9), 1720-1724, 2019 | 170 | 2019 |
| Impact of mammographic screening on the detection of good and poor prognosis breast cancers LJ Esserman, Y Shieh, EJT Rutgers, M Knauer, VP Retèl, S Mook, ... Breast cancer research and treatment 130, 725-734, 2011 | 130 | 2011 |
| Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer VP Retèl, MA Joore, M Knauer, SC Linn, M Hauptmann, WH van Harten European journal of cancer 46 (8), 1382-1391, 2010 | 117 | 2010 |
| Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study … WJ Koemans, RT van der Kaaij, H Boot, T Buffart, AAFA Veenhof, ... BMC cancer 19, 1-8, 2019 | 107 | 2019 |
| Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature S Mook, M Knauer, JM Bueno-de-Mesquita, VP Retel, J Wesseling, ... Annals of surgical oncology 17, 1406-1413, 2010 | 105 | 2010 |
| Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized … S Koole, R van Stein, K Sikorska, D Barton, L Perrin, D Brennan, ... International Journal of Gynecological Cancer 30 (6), 888-892, 2020 | 97 | 2020 |
| A systematic and critical review of the evolving methods and applications of value of information in academia and practice L Steuten, G van de Wetering, K Groothuis-Oudshoorn, V Retèl Pharmacoeconomics 31, 25-48, 2013 | 85 | 2013 |
| A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy VP Retèl, L van der Molen, FJM Hilgers, CRN Rasch, AA l'Ortye, ... BMC cancer 11, 1-9, 2011 | 62 | 2011 |
| Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial SN Koole, C Van Lieshout, WJ Van Driel, E Van Schagen, K Sikorska, ... Journal of Clinical Oncology 37 (23), 2041-2050, 2019 | 52 | 2019 |
| Integration of a smoking cessation program in the treatment protocol for patients with head and neck and lung cancer JC de Bruin-Visser, AH Ackerstaff, H Rehorst, VP Retèl, FJM Hilgers European Archives of Oto-Rhino-Laryngology 269, 659-665, 2012 | 49 | 2012 |
| Scenario drafting to anticipate future developments in technology assessment VP Retèl, MA Joore, SC Linn, EJT Rutgers, WH van Harten BMC research notes 5, 1-12, 2012 | 46 | 2012 |
| Understanding the costs of surgery: a bottom-up cost analysis of both a hybrid operating room and conventional operating room S Patel, M Lindenberg, MM Rovers, WH Van Harten, TJM Ruers, L Poot, ... International journal of health policy and management 11 (3), 299, 2020 | 45 | 2020 |
| Determinants and effects of positive surgical margins after prostatectomy on prostate cancer mortality: a population-based study VP Retèl, C Bouchardy, M Usel, I Neyroud-Caspar, F Schmidlin, G Wirth, ... BMC urology 14, 1-11, 2014 | 45 | 2014 |
| Knowledge of genomic testing among early‐stage breast cancer patients AR Richman, JP Tzeng, LA Carey, VP Retèl, NT Brewer Psycho‐Oncology 20 (1), 28-35, 2011 | 44 | 2011 |
| The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2− early breast cancer R Exner, Z Bago-Horvath, R Bartsch, M Mittlboeck, VP Retel, F Fitzal, ... British journal of cancer 111 (5), 837-842, 2014 | 42 | 2014 |
| Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics VP Retèl, JM Bueno-de-Mesquita, MJM Hummel, MJ van de Vijver, ... International journal of technology assessment in health care 25 (1), 73-83, 2009 | 41 | 2009 |
| Review on early technology assessments of nanotechnologies in oncology VP Retèl, MJM Hummel, WH van Harten Molecular oncology 3 (5-6), 394-401, 2009 | 40 | 2009 |
